{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:46:32Z","timestamp":1775011592158,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11096-023-01580-2","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:33:54Z","timestamp":1682004834000},"page":"875-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-611X","authenticated-orcid":false,"given":"Munenobu","family":"Kashiwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"Suppl5","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl5):v28-37. https:\/\/doi.org\/10.1093\/annonc\/mdw324.","journal-title":"Ann Oncol."},{"key":"1580_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474124.2021.1890031","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15:547\u201354. https:\/\/doi.org\/10.1080\/17474124.2021.1890031.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"1580_CR3","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1200\/EDBK_160831","volume":"35","author":"JA Bridgewater","year":"2016","unstructured":"Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194\u2013203. https:\/\/doi.org\/10.1200\/EDBK_160831.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1580_CR4","unstructured":"Cancer statistics. Japan: Cancer Information Service, National Cancer Center (Vital Statistics of Japan, Ministry of Health, Labour and Welfare).\u00a0https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html#a7. Accessed 16 Oct 2022."},{"key":"1580_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S, et al. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23:149\u201357. https:\/\/doi.org\/10.1002\/jhbp.314.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1580_CR6","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: An updated comprehensive review. Ann Hepatol. 2022;27:100737. https:\/\/doi.org\/10.1016\/j.aohep.2022.100737","journal-title":"Ann Hepatol."},{"key":"1580_CR7","doi-asserted-by":"publisher","first-page":"100503","DOI":"10.1016\/j.esmoop.2022.100503","volume":"7","author":"O Mirallas","year":"2022","unstructured":"Mirallas O, L\u00f3pez-Valbuena D, Garc\u00eda-Illescas D, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open. 2022;7:100503.","journal-title":"ESMO Open."},{"key":"1580_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"key":"1580_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for Biliary Tract Cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med."},{"key":"1580_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6605779.","journal-title":"Br J Cancer."},{"key":"1580_CR11","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz402.","journal-title":"Ann Oncol."},{"key":"1580_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30:102\u201310. https:\/\/doi.org\/10.1002\/jhbp.1219.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1580_CR13","doi-asserted-by":"crossref","unstructured":"Nagino M, Hirano S, Yoshitomi H et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd. English ed. J Hepato Biliary Pancreatic Sci. ISBN: 0000000329118; 2021","DOI":"10.1002\/jhbp.870"},{"key":"1580_CR14","unstructured":"Center for Outcomes Research and economic evaluation for health. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council version 3.0.; 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed 16 Oct 2022"},{"key":"1580_CR15","unstructured":"O.E.C.D. Data. Exchange rates. https:\/\/data.oecd.org\/conversion\/exchange-rates.htm#indicator-chart. Accessed 16 Oct 2022"},{"key":"1580_CR16","first-page":"1034","volume":"54","author":"Japanese Society of Nephrology","year":"2012","unstructured":"Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012 [in Japanese]. Nihon Jinzo Gakkai Shi. 2012;54:1034\u2013191.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"1580_CR17","unstructured":"Reimbursement schedule of social insurance.\u00a02022. Tokyo, Japan: Ministry of Health, Labor and Welfare.\u00a0https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00037.html. Accessed 16 Oct 2022.\u00a0"},{"key":"1580_CR18","unstructured":"National health insurance drug price. Standard. Tokyo, Japan: Jiho Inc. ISBN: 9784840754040; 2022."},{"key":"1580_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, et al. History and profile of diagnosis Procedure Combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:1\u201311. https:\/\/doi.org\/10.2188\/jea.JE20200288.","journal-title":"J Epidemiol"},{"key":"1580_CR20","unstructured":"Ministry of Health., Labour and Welfare, Diagnostic Procedure Classification (DPC) electronic score table. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000198757_00004.html. Accessed 16, Oct 2022."},{"key":"1580_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jjco\/hyy030","volume":"48","author":"O Miyake","year":"2018","unstructured":"Miyake O, Murata K, Tanaka S, et al. Costs associated with febrile neutropenia in japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol. 2018;48:410\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyy030.","journal-title":"Jpn J Clin Oncol"},{"key":"1580_CR22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/ggi.12977","volume":"17","author":"K Kato","year":"2017","unstructured":"Kato K, Fukuda H. Comparative economic evaluation of home-based and hospital-based palliative care for terminal cancer patients. Geriatr Gerontol Int. 2017;17:2247\u201354. https:\/\/doi.org\/10.1111\/ggi.12977.","journal-title":"Geriatr Gerontol Int"},{"key":"1580_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00280-014-2648-9","volume":"75","author":"M Kanai","year":"2015","unstructured":"Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine\/cisplatin\/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015;75:293\u2013300. https:\/\/doi.org\/10.1007\/s00280-014-2648-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40273-018-0630-9","volume":"36","author":"IA Tikhonova","year":"2018","unstructured":"Tikhonova IA, Huxley N, Snowsill T, et al. Economic analysis of first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England. Pharmacoeconomics. 2018;36(7):837\u201351. https:\/\/doi.org\/10.1007\/s40273-018-0630-9.","journal-title":"Pharmacoeconomics."},{"key":"1580_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"1580_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.21873\/anticanres.14026","volume":"40","author":"J Sgouros","year":"2020","unstructured":"Sgouros J, Aravantinos G, Koliou GA, et al. First line gemcitabine\/pazopanib in locally advanced and\/or metastatic biliary tract carcinoma. A hellenic cooperative oncology group phase II study. Anticancer Res. 2020;40:929\u201338. https:\/\/doi.org\/10.21873\/anticanres.14026.","journal-title":"Anticancer Res"},{"key":"1580_CR27","doi-asserted-by":"publisher","first-page":"871262","DOI":"10.3389\/fphar.2022.871262","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Zhang Y, Lin K, et al. Cost-effectiveness analysis of capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers. Front Pharmacol. 2022;13:871262. https:\/\/doi.org\/10.3389\/fphar.2022.871262.","journal-title":"Front Pharmacol"},{"key":"1580_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12029-010-9242-0","volume":"43","author":"JA Roth","year":"2012","unstructured":"Roth JA, Carlson JJ. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer. 2012;43:215\u201323. https:\/\/doi.org\/10.1007\/s12029-010-9242-0.","journal-title":"J Gastrointest Cancer"},{"key":"1580_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","volume":"48","author":"I Tsukiyama","year":"2017","unstructured":"Tsukiyama I, Ejiri M, Yamamoto Y, et al. A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan. J Gastrointest Cancer. 2017;48:326\u201332. https:\/\/doi.org\/10.1007\/s12029-016-9885-6.","journal-title":"J Gastrointest Cancer"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01580-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T23:19:04Z","timestamp":1702250344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01580-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2209279\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}